Recent data from a phase 2 study (NCT03931291) was presented, which assessed eprenetapopt/AZA as post-alloHSCT maintenance in patients with TP53-mutant MDS and AML [161]. This evidence concerns the gene TP53 and myelodysplastic syndrome.